|
Trimedyne,
Inc. is a manufacturer of lasers and disposable fiber optic
delivery devices for use in a variety of surgical applications
including, urology, orthopedics, ENT surgery, gynecology, GI
surgery, and general surgery. Trimedyne's lasers and proprietary
delivery systems are designed to reduce the bleeding and trauma
of conventional surgery, reduce or eliminate hospital bed stays
and shorten recuperation time.
Cardiodyne, a 90% subsidiary of Trimedyne is developing a heart
revascularization laser system for cardiovascular surgeons and
cardiologists to treat coronary artery disease, the largest
single killer among medical conditions and diseases.
Trimedyne is a publicly traded company, listed on the NASDAQ
National Market System under the symbol "TMED."
1980
|
Company Founded |
1982
|
Acquired Fiber Optics Company |
1983
|
IPO ($1.20 per share) |
1987
|
First laser approved for sale by FDA for treating
blockages in peripheral (below the waist) arteries
|
1992 |
Holmium laser cleared for sale by FDA for use in
arthroscopy
|
1994 |
Holmium laser cleared for sale by FDA for use in urology
|
1995 |
Launched 80 watt Holmium laser - OmniPulse MAX™
|
1996 |
First laser device cleared for sale by FDA for treating
enlarged prostates
|
1997 |
OmniTip™
switchable tips cleared for sale by FDA
|
1998 |
Reusable bare fiber cleared for sale by FDA
|
1999 |
Laser Needle cleared by FDA for use in
decompression of lumbar ( herniated ) spinal discs
|
2000 |
Joint marketing agreement with Surgical Innovations
& Services ( SIS ) |
Top of
Page |
